<DOC>
	<DOC>NCT01545050</DOC>
	<brief_summary>The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn's disease and who have had an insufficient response to conventional therapy or have failed Anti-Tumor Necrosis Factor (anti-TNF) therapy.</brief_summary>
	<brief_title>Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Confirmed Crohn's Disease diagnosis via radiology, endoscopy or histology within prior 12 months. Diagnosed for at least 3 months Active Disease with Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450 Failed conventional therapy or steroid dependent Diagnosed/clinical findings of Ulcerative Colitis (UC), indeterminate colitis, non colonic/ileal disease Stricture/stenosis, Stoma, proctocolectomy, subtotal colectomy, ileorectal anastomosis History of diverticulitis, or evidence of Gastrointestinal (GI) perforations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>